APOA5

Across TCGA pan-cancer cohorts, APOA5 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated APOA5 data layer compared with 20 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher APOA5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated APOA5 expression acts as an unfavorable survival marker.

SCLC, UCEC, and LUSC are the cancer types where APOA5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	All	0.140	0.853	<.001	15	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LUSC	OS	Median	II,III,IV	0.073	0.733	<.001	6	view →
ESCA	OS	Median	All	0.147	0.700	.002	6	view →
COAD	OS	Median	II,III,IV	0.454	0.791	.015	3	view →
SKCM	OS	Median	III,IV	0.245	0.721	.018	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

APOA5–SCLC (OS)

Open the SCLC breakdown →